Warning: Clinic Releaf® are deliberately charging patients over MSRP for medication through a partner pharmacy, without making other pharmacies available to their patients.
All patients must be offered free choice in pharmacy without influence nor penalty to avoid non-compliant 'prescription direction' breaking GMC and BMA guidelines - risking prescribing clinician's licence to practice.

Back to Noidecs or All Bud/Flower

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This page was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Dosing Look-Up Table (Estimated)

0.01/g1.6/mg THC0.1/mg CBD
0.05/g8/mg THC0.5/mg CBD
0.1/g16/mg THC1/mg CBD
0.15/g24/mg THC1.5/mg CBD
0.2/g32/mg THC2/mg CBD
0.25/g40/mg THC2.5/mg CBD
0.3/g48/mg THC3/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
United Kingdom Noidecs
Designation
T16
Cultivar/Strain
L.A. Amnesia
Classification
Sativa Hybrid
Chemotype
Type I: High THC
Flower Provided
Ground Bud
THC Potential Range (±10%)
14.4-17.6%
CBD Potential Range (±10%)
1%
Cultivated/Produced by
Australia Cannatrek
Cultivated or Packaged in
Flag of Australia Australia
Irradiation
Gamma-Irradiated
Imported by
United Kingdom Eaststone
Imported as
Schedule II: Finished Product

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Discontinued

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

Project Twenty21

Available on T21, a research project offering participating patients several discounted medications:

Product Description Video Reviews0 Patient Reviews

About L.A. Amnesia

LAASativa Hybrid

L.A. Amnesia combines the genetics of the world famous Dutch strain, Amnesia Haze, with a highly potent Kush variety.

Dutch Flag Dutch Bred, American Flag American Genetics

L.A. Amnesia is a potent, high yield sativa with a revved up THC count and is the result of a collaboration between the legendary growers of Paradise Seeds and legendary cannasseur, Tommy Chong.

We were looking for a very special sativa to bring to the exclusive Tommy Chong’s™ line and this is definitely it. L.A. Amnesia combines the genetics of the world famous Dutch strain, Amnesia Haze, with a highly potent Kush variety. Named after Los Angeles, this heavenly strain is a perfect match for the City of Angels!

Description provided by Paradise-Seeds.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

United Kingdom About Lyphe Group Ltd

Noidecs Logo

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)